Effectiveness of a Pharmacogenetic Tool at Improving Treatment Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Clinical Studies
Several pharmacogenetic tests to support drug selection in psychiatric patients have recently become available. The current meta-analysis aimed to assess the clinical utility of a commercial pharmacogenetic-based tool for psychiatry (Neuropharmagen<sup>®</sup>) in the treatment...
Main Authors: | Silvia Vilches, Miquel Tuson, Eduard Vieta, Enric Álvarez, Jordi Espadaler |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/11/9/453 |
Similar Items
-
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial
by: Víctor Pérez, et al.
Published: (2017-07-01) -
Pharmacogenetics of antidepressant drugs: An update
by: Crisafulli Concetta, et al.
Published: (2014-01-01) -
Pharmacogenetics of antidepressants
by: Concetta eCrisafulli, et al.
Published: (2011-02-01) -
Pharmacogenetic-Guided Antidepressant Selection as an Opportunity for Interprofessional Collaboration: A Case Report
by: Céline K. Stäuble, et al.
Published: (2021-07-01) -
Clinical Phenotypes Characterization in Pharmacogenetics Testing Trials for Major Depressive Disorder Treatment
by: A. Minelli
Published: (2022-06-01)